Drugs Acting on the Neuromuscular Junction (NMJ)

MS-Ph-001 | Block Exam Prep | 1st Year MBBS Pharmacology

Part 1: Normal NMJ Physiology (Essential Background)

1. A nerve impulse travels down the lower motor neuron to the presynaptic terminal
2. The action potential opens voltage-gated Ca²+ channels (VGCa²+) at the nerve terminal
3. Ca²+ influx causes ACh-loaded vesicles to fuse with the presynaptic membrane and release ACh into the synaptic cleft (~50-70 nm wide)
4. ACh diffuses across the cleft and binds to nicotinic ACh receptors (nAChR) on the postjunctional muscle membrane
5. Each nAChR is a pentamer: 2α + β + δ + ε (mature) - ACh must bind both α subunits simultaneously to open the ion channel
6. Channel opening allows Na+ influx / K+ efflux → end-plate potential (EPP) → action potential propagated along muscle → contraction
7. Acetylcholinesterase (AChE) in the synaptic cleft rapidly hydrolyzes ACh (within ~200 μsec) → end-plate repolarizes → channel closure → muscle relaxes

NMJ diagram: Katzung's Basic & Clinical Pharmacology, 16th Ed.

Learning Objective 1: Mechanism by Which Drugs STIMULATE the NMJ

A. Cholinesterase Inhibitors (Indirect Stimulation) - MOST IMPORTANT

• After AChE inhibition, ACh remains in the synapse longer
• It diffuses laterally and cycles through multiple association-dissociation events with neighboring receptors
• This prolongs the end-plate potential decay time
• Quanta released by individual nerve impulses are no longer isolated
• Result: asynchronous excitation and muscle fasciculations
• With enough inhibition: continuous end-plate depolarization and, paradoxically, depolarizing blockade (see below)
• Anti-ChE agents also stimulate the axon terminal itself, causing antidromic firing of the motor neuron, contributing to fasciculations of the entire motor unit

Key clinical use: Anti-ChE agents reverse nondepolarizing NMJ blockade by increasing ACh to outcompete the blocker. They do NOT reverse and actually worsen depolarizing blockade (succinylcholine).

B. Depolarizing Agonists (Direct Stimulation then Block)

• Succinylcholine (and nicotine at high doses) acts as a nicotinic receptor agonist
• It binds nAChRs and generates a muscle action potential - initially causing muscle fasciculations (the "stimulation" phase)
• Because it is NOT metabolized by AChE, its concentration in the synaptic cleft remains high
• This is technically both stimulation AND the mechanism of its eventual block (see Part 2 below)

C. Presynaptic K+ Channel Blockers (Stimulate ACh Release)

• 4-Aminopyridine and amifampridine block presynaptic K+ channels
• This prolongs the nerve action potential, increases Ca²+ influx → more ACh vesicle release
• Used therapeutically in Lambert-Eaton Myasthenic Syndrome (LEMS) where antibodies attack VGCa²+ channels and reduce ACh release

Learning Objective 2: Mechanism by Which Drugs BLOCK the NMJ

Mechanism 1: Nondepolarizing Block (Competitive Antagonism)

• These drugs are quaternary ammonium compounds structurally related to ACh
• They bind to both α-subunits of the nAChR (or even just one is enough to block)
• They do NOT activate the receptor - they prevent ACh from binding
• No ion channel opening occurs → no end-plate potential → flaccid paralysis
• They act as competitive antagonists - their block can be overcome by increasing ACh (e.g., with neostigmine)
• Nondepolarizing drugs also block presynaptic α3β2 nAChRs, reducing ACh mobilization for subsequent nerve signals - this causes "fade" on train-of-four (TOF) nerve stimulation testing

• No initial fasciculations
• Fade on TOF stimulation (because presynaptic receptors are blocked)
• Post-tetanic facilitation present
• Reversed by: anticholinesterases (neostigmine, edrophonium) or sugammadex (for rocuronium/vecuronium)

Mechanism 2: Depolarizing Block (Phase I and Phase II)

1. Succinylcholine mimics ACh and binds nAChRs as a full agonist
2. It opens ion channels → initial fasciculations (brief muscle twitching)
3. Unlike ACh, succinylcholine is NOT hydrolyzed by AChE - it persists at the end-plate
4. Sustained end-plate depolarization → perijunctional Na+ channels become inactivated (they cannot reopen during continuous depolarization)
5. The end-plate cannot repolarize because succinylcholine is still occupying receptors
6. Result: flaccid paralysis despite the drug being a receptor agonist

Sodium channels rapidly inactivate with continuing depolarization. After opening and initial depolarization, the Na+ channel's time-dependent lower gate closes and cannot reopen until the membrane repolarizes. As long as succinylcholine holds the receptor open, repolarization cannot occur and Na+ channels remain stuck inactivated. (Morgan & Mikhail's Clinical Anesthesiology, 7e)

• With prolonged or repeated succinylcholine exposure, the block transitions to Phase II
• Receptors enter a prolonged closed/desensitized state despite the agonist still being present
• Clinically resembles nondepolarizing block
• The exact mechanism is uncertain but involves receptor desensitization

• Initial fasciculations before paralysis (unlike nondepolarizing)
• No fade on TOF (depolarizers don't block presynaptic α3β2 receptors)
• No post-tetanic facilitation
• NOT reversed by anticholinesterases (neostigmine will worsen it)
• Reversed by: waiting for spontaneous recovery (succinylcholine is metabolized by pseudocholinesterase/plasma cholinesterase in blood)

Other Mechanisms of Block (Additional)

Summary Comparison Table

High-Yield Points for Your Exam

1. Two mechanisms of NMJ block: (1) competitive antagonism of nAChR (nondepolarizing) vs. (2) persistent depolarization via agonist (depolarizing)
2. Succinylcholine = depolarizing blocker = ACh receptor agonist → causes initial fasciculations → then flaccid paralysis
3. Nondepolarizing blockers = competitive antagonists at nAChR → no fasciculations
4. Neostigmine stimulates NMJ indirectly by inhibiting AChE → reverses nondepolarizing block but worsens depolarizing block
5. Botulinum toxin and Mg²+ excess block NMJ by preventing presynaptic ACh release
6. 4-Aminopyridine stimulates NMJ by blocking presynaptic K+ channels → more Ca²+ influx → more ACh release (used in LEMS)
7. ACh receptor structure: pentamer with 2α subunits - both must be bound by ACh to open; blocking even one α subunit prevents opening